<DOC>
	<DOCNO>NCT02260180</DOCNO>
	<brief_summary>The purpose study evaluate safety dose-response 2 concentration A-101 versus vehicle control treatment seborrheic keratosis .</brief_summary>
	<brief_title>Study A-101 Treatment Seborrheic Keratosis</brief_title>
	<detailed_description>The main objective study evaluate dose-response relationship 2 concentration A-101 Solution match A-101 Solution Vehicle apply SK target lesion face . A objective evaluate safety efficacy 2 concentration A-101 Solution match A-101 Solution Vehicle apply topically 2 time SK target lesion face .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Keratosis , Seborrheic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Subject least 18 year age 2 . Subject Fitzpatrick skin type 14 3 . Subject clinical diagnosis stable clinically typical seborrheic keratosis 4 . Subject 1 appropriate seborrheic keratosis target lesion , define ( Section 5.4 ) , face : Have clinically typical appearance Be treatment naïve Have PLA ≥2 ( Section 6.1.2 ) Have long axis ≥7mm ≤15mm ( Section 5.4 ) Have long dimension perpendicular long axis ≥7mm ≤15mm ( Section 5.4 ) Have thickness ≤2mm Be discrete lesion Be , center area outline provide 3cm diameter circular template , seborrheic keratosis lesion present Not eyelids Not within 5mm orbital rim Not cover hair , investigator 's opinion , would interfere study medication application study evaluation ( NB : study medication may bleach hair ) Not intertriginous fold Not pedunculated . 5 . If subject woman childbearing potential , negative urine pregnancy test agree use approve effective method birth control ( Section 8 ) duration study 6 . Subject nonpregnant nonlactating 7 . Subject good general health free know disease state physical condition , investigator 's opinion , might impair evaluation target lesion expose subject unacceptable risk study participation 8 . Subject willing able follow study instruction attend study visit 9 . Subject able comprehend willing sign Informed Consent Form ( ICF ) . 1 . Subject clinically atypical and/or rapidly grow seborrheic keratosis lesion 2 . Subject presence multiple eruptive seborrheic keratosis lesion ( Sign LesserTrelat ) 3 . Subject current systemic malignancy 4 . Subject history keloid formation hypertrophic scar 5 . Subject use follow systemic therapy within specified period prior Visit 1 : Retinoids ; 180 day Glucocorticosteroids ; 28 day Antimetabolites ( e.g. , methotrexate ) ; 28 day 6 . Subject use follow topical therapy within specified period prior Visit 1 , proximity target lesion , investigator 's opinion , interfere application study medication study assessment : LASER , light ( e.g. , intense pulse light [ IPL ] , photodynamic therapy [ PDT ] ) energy base therapy ; 180 day Retinoids ; 28 day Liquid nitrogen , electrodesiccation , curettage , imiquimod , 5flurouracil , ingenol mebutate ; 60 day Glucocorticosteroids antibiotic ; 14 day 7 . Subject currently follow within specified period prior Visit 1 , proximity target lesion , investigator 's opinion , interfere application study medication study assessment : A cutaneous malignancy ; 180 day Experienced sunburn ; 28 day A premalignancy ( e.g. , actinic keratosis ) ; currently Body art ( e.g. , tattoo , piercing , etc . ) ; currently Excessive tan ; currently 8 . Subject history sensitivity ingredient study medication 9 . Subject current skin disease ( e.g. , psoriasis , atopic dermatitis , eczema , sun damage , etc . ) , condition ( e.g. , sunburn , excessive hair , open wound ) , investigator 's opinion , might put subject undue risk study participation interfere study conduct evaluation 10 . Subject participate investigational drug trial administration investigational study medication occur within 30 day prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>